TLDR: Accent Therapeutics Raises $75M in Series C Funding

Accent Therapeutics, a biopharmaceutical company focused on small molecule precision cancer therapies, has raised $75 million in Series C funding. The round was led by Mirae Asset Capital Life Science, with participation from other new investors including Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb, and Johnson & Johnson Innovation. Existing investors, such as The Column Group, Atlas Venture, and AbbVie Ventures, also participated in the round.

The funding will be used to advance Accent Therapeutics’ lead programs, including a first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor. These programs will undergo early clinical development, including safety, pharmacokinetics, and early efficacy studies.

Accent Therapeutics specializes in small molecule precision cancer therapies that target critical intracellular dependencies in various types of cancer. The company’s DHX9 inhibitor aims to address indications with high unmet needs, such as breast, ovarian, colorectal, endometrial, and gastric cancers. The KIF18A inhibitor has the potential to benefit patients with ovarian cancer and triple negative breast cancer.

Naveen Krishnan, MD, MPhil, Managing Director of Mirae Asset Capital Life Science, will join Accent Therapeutics’ Board of Directors as part of the financing deal.